淋巴瘤

预约门诊

淋巴瘤生存率

不同类型淋巴瘤的生存率各不相同。生存率还取决于您的整体健康状况、癌症分期以及所接受的治疗方案。为了解淋巴瘤的生存率，专家会研究大量淋巴瘤患者，观察他们在确诊后 5 年内的存活人数。

对于 1 期霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率为 92%。随着癌症扩散，存活概率会降低。对于 4 期霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率约为 82%。

对于 1 期非霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率为 87%。随着癌症扩散，存活概率会降低。对于 4 期非霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率约为 63%。

需注意生存统计数据需要 5 年时间采集。最新的生存率数据包含 5 年前接受过淋巴瘤治疗的患者。这些患者可能未接触过最新疗法。在过去数十年间，淋巴瘤的死亡率持续下降，生存率稳步提升。

申请预约
分期医生与科室
Jan. 13, 2026

Living with 淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

dtrgran59
What are my chances that MGUS turns into multiple myeloma?

39 Replies Wed, Jan 14, 2026

patientk
Anybody else have Factor V Leiden?

66 Replies Wed, Jan 14, 2026

See more discussions
  1. Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Accessed Aug. 6, 2025.
  2. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Aug. 6, 2025.
  3. Primary CNS lymphoma treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq. Accessed Aug. 6, 2025.
  4. Mycosis fungoides (including Sezary Syndrome) treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq. Accessed Aug. 6, 2025.
  5. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Aug. 6, 2025.
  6. Cancer stat facts: Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed Aug. 6, 2025.
  7. Elsevier Point of Care. Clinical Overview: Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  8. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  9. Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  10. Larson RA, et al. Tumor lysis syndrome: Prevention and treatment. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  11. Elsevier Point of Care. Clinical Overview: Febrile neutropenia in adults. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  12. Robetorye R, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019-00344-0.
  13. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  14. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Aug. 6, 2025.
  15. Membership institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Aug. 6, 2025.

相关

相关医疗程序

Mayo Clinic 新闻

产品与服务

淋巴瘤

CON-20304579